<DOC>
	<DOCNO>NCT02104388</DOCNO>
	<brief_summary>The purpose study determine SJP-0035 ophthalmic solution effective promote corneal epithelial wound heal condition associate corneal epithelial disorder .</brief_summary>
	<brief_title>Safety Efficacy Study SJP-0035 Ophthalmic Solution Patients With Moderate Severe Corneal Epithelial Disorders</brief_title>
	<detailed_description>There currently product approve corneal epithelial wound healing . A Phase 1 Study SJP-0035/1-01 conduct healthy volunteer investigate safety , tolerability , pharmacokinetic profile SJP-0035 ophthalmic solution determine appropriate dose evaluate patient moderate severe corneal epithelial disorder . This Phase 2a study conduct evaluate safety efficacy SJP-0035 ophthalmic solution patient promote corneal epithelial wound heal condition associate corneal epithelial disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female age 18 75 year , inclusive . Has moderate severe superficial punctate keratitis ( SPK ) and/or corneal erosion 1 eye . Has symptom cause corneal epithelial disorder . Has obtain improvement previous treatment SPK corneal erosion within last 30 day . Is female childbearing potential negative pregnancy test result Screening baseline agree use effective contraception throughout study postmenopausal woman negative pregnancy test result Screening baseline . Has corneal stromal endothelial abnormality include active bacterial viral ocular infection , bullous keratopathy , chemical burn trauma cornea . Any active chronic allergic , bacterial , viral infection ocular adnexa eye structure . Had previous ocular/refractive surgery ( include laser surgery ) within last 6 month . Has use ocular medication ( except mydriatic , stain , topical anesthesia use study assessment ) within 14 day prior first dose study drug , anticipate require medication study . Artificial tear may use 72 hour prior first dose . Is unable discontinue Restasis . A 28day washout period prior first dose study drug require . Is contact lens wearer discontinue use duration study . Alcohol drug abuse within past 6 month . Positive hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus test Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>